|
[Notice] 2004 Pharmaceutical Reevaluation Results
2005.06.30
|
|---|
|
In accordance with Article 26-3 and Article 34, Paragraph 4 of the Pharmaceutical Affairs Act and [Regulations on the Implementation of Drug Reevaluation (KFDA Notification)], reevaluation was conducted on [2 therapeutic groups of artificial perfusion agents, 22 sites, 141 items] and [4 other metabolic therapeutic groups, 55 sites, 848 items], and the results are hereby announced.
Affected products include: Glizide Tablets (Gliclazide) Daien Capsules (Green Tea Powder, Ortho-Ciphen Powder) Bronase Tablets (Deoxyribonuclease, Bromelain)
For inquiries related to this announcement:
Responsible Department: Daehan New Pharm Development Division
Contact: 02-3415-7857 |


Home